Neurobiology research has used an essentially reductionist approach for many years, dissecting out the brain in more simple elements. Recent technical advances, like systems biology, have made now possible to embrace a more holistic vision and try to tackle the complexity of the system. In this short review, we describe how these approaches, in particular analyses or gene networks and of microRNAs, may be useful for epilepsy research. We will describe and discuss recent studies that illustrate how these research approaches can lead to the identification of therapeutic targets and pharmacological strategies to prevent or treat some forms of epilepsy. We aim to show that studying epilepsy and its comorbidities within a complex system framework is a promising integration to the traditional reductionist approaches, and that it will become more and more important in the future for developing new therapies.
Systems biology
The approach to research in neurobiology has changed in the past few decades: the historic reductionist approach is now paired with a more holistic vision. Reductionism can be traced back to Bacon and Descartes: the first stated that laws derived from specific cases should be used to elaborate general predictions, while the second proposed to divide a problem in many little case studies and solve them one by one [1] . From the early 50's, more integrated approaches gained importance in molecular biology and more recently, starting with the Human Genome Project, new, holistic systems biology approaches were developed. Reductionism gives significance to one factor at a time and considers systems as linear and predictable [1] . Systems biology views at different factors as capable of describing a behavior, and considers systems as nonlinear and nonpredictable on the basis of knowledge of their single components. An initial theory of systems was proposed by Beralanffy [2] , who was seeking a way to study the organism as a whole and not as the sum of individual parts, and proposed means to unify mathematical models and biology. It must be emphasized that, without the results obtained using reductionist approaches, important notions about genes, molecules, and processes would not exist. Thus, the aim of systems biology is not to substitute more traditional approaches but, rather, to find connecting links at higher levels, prioritizing networks against single elements (for example, molecules or cells).
In a reductionist framework, a mechanism underlying a disease is identified within the components of the system itself. This could lead to misinterpretations, because it is well-known that, for example, a loss of function or a mutation of a single gene may not be sufficient to produce a disease and complex diseases are the results of multiple mechanisms that interfere one with another. Therefore, analyzing single components may be insufficient to clarify the mechanisms of disease in complex biological systems.
A complex system is any system featuring large numbers of interacting components whose aggregate activity is nonlinear (not derivable from the summation of the activities of the individual components) and that exhibits hierarchical self-organization. The brain is a quintessential complex system (Fig. 1) . Important features of complex systems include the following: no level is biologically more relevant than any other; each level is required for the level above it and may feedback to the level below it (hierarchy); prediction of how a level will behave as a function of a change in a lower/upper level is uncertain because of compensatory mechanisms, redundancy, interactions (nonlinearity); the impact of interventions at higher levels of the hierarchy could be easier to predict as there are fewer nonlinear steps; a complex system spontaneously acquires order without direction from external agents (self-organization); modification of an Epilepsy & Behavior xxx (xxxx) xxx input will alter the way the system self-organizes, and this will influence the characteristics of the emergent behavior.
Systems genetics
Systems genetics is the part of systems biology that aims to "understand how genetic information are integrated, coordinated, and ultimately transmitted through molecular, cellular, and physiological networks, to enable the higher-order functions and emergent properties of biological systems" [3] . Through systems genetics it is possible to study multiple genetic perturbations rather than individual ones [4] . Well-established qualitative techniques have been paired with quantitative ones, such as next generation sequencing (NGS), which permit to study the whole transcriptome of a given cell, also offering Fig. 1 . The brain as a complex system. At the most basal level, the system can be represented as a collection of networks where different types of molecules (nucleic acids, proteins) interact. These molecular networks entail the essential properties of complex systems (emergency of properties that cannot be found in its individual elements; capacity to maintain the main functions or readapt under environmental perturbations; high connection of elements sharing similar functions). They produce emerging properties that affect the hierarchically higher levels (individual cells, neuronal networks, whole brain), and these higher levels feedback on the organization of the molecular networks. See text for further details.
the opportunity to discover novel transcripts or to reveal sequence variations. Transcriptome sequencing can be seen as a molecular fingerprint, and finding perturbations in the gene expression networks may lead to the discovery of disease mechanisms [5] . Data derived from sequencing studies can be put together in genome-wide associations studies (GWAS) to search for small variations within the genome analyzed; normally, the most common type of genetic variation is single nucleotide polymorphisms (SNPs) [6] .
At the most basal level, biological systems can be represented as networks where different types of molecules (nucleic acids, proteins) interact. Coherently with the general features of complex systems, these molecular networks entail some essential properties [7] : 1) emergence: the links between the elements of the network can lead to the emergency of properties that cannot be found in its individual elements;
2) robustness: biological systems are capable of maintaining their main functions under perturbations driven by the environment, or readapt and create new interactive networks; 3) modulation: elements sharing similar functions are highly connected one with another.
In must be kept in mind, as already stated above, that molecular networks are at the basis of the pyramid. They have their internal organization and produce emerging properties that affect the hierarchically higher levels, but these higher levels feedback on the organization of the molecular networks. Therefore, a gene mutation may cause a protein to function improperly and trigger a cascade of events that may lead to the development of a disease [8] . However, it may not necessarily lead to that disease, because the system as a whole may generate effective counter-mechanisms to oppose those generated by the pathological protein. For the same reason, even pathological molecular networks may not necessarily lead to development of a disease.
Relevance for epilepsy
Epilepsy is an example of a complex disease: not only because it is a neurological disease, and the brain is the most complex organ, but also because of its enormous heterogeneity. In the past few years, thousands of genetic variations have been identified in clinical and preclinical studies that associate with epileptic phenotypes. A major unresolved issue is why a single mutation can lead to many different outcomes: a gene variant in a single molecular pathway can in fact be associated with different types of epilepsy in different patients [8] . Even though it can be difficult to identify identical mutations across different patients affected by the same form of epilepsy, different mutations may affect the same functional pathway(s), which can be identified by mapping interactions of the different causal genes, that is, searching modules enriched with the altered genes. Within this approach, regulatory factors capable of orchestrating the activation of the pathological module may be proposed as therapeutic targets.
Below, we describe how this approach may be exploited, taking as examples findings to which our lab has contributed.
Epilepsy gene networks
One example of how systems biology and gene-network study approaches have been employed in epilepsy research is the work by Johnson and colleagues [9] , that let to identification of Sestrin 3 (SESN3) as a master regulator of a gene network module associated with epilepsy.
The starting question was if the transcriptome in the epileptic hippocampus is organized into gene coexpression networks. In order to pursue an answer, whole-genome expression profiles were obtained from surgically resected hippocampi from 129 patients with temporal lope epilepsy (TLE). Graphical Gaussian Models (GGMs, tools to study gene association networks) were used to analyze the data and identified a large coexpression network comprising 442 genes. To establish if this network was causally related to epilepsy, data were integrated with genetic susceptibility data. Genome-wide associations studies data from a separate cohort of patients (1429 patients with TLE) were compared to 7358 healthy controls: the TLE network as a whole was highly enriched for genetic associations to epilepsy compared with genes not in the network, indicating a causal involvement of the TLE-network in epilepsy etiology.
This coexpressed gene network clustered into two functionally homogenous transcriptional modules (i.e., subnetworks of highly correlated genes): Module-1, comprising 69 genes enriched for gene ontology (GO) categories related to inflammation (IL-1 signaling cascade and TLR-signaling pathway); and Module-2, comprising 54 genes enriched for cell-to-extracellular matrix adhesion processes. These subnetworks, and in particular Module-1, were conserved across species, as the genes were found upregulated also in an animal model of epilepsy.
However, the key step was to identify genetic variants that regulate the gene coexpression modules (i.e. regulatory 'hotspots'). Evidence of genetic regulation of module expression can be obtained using genome-wide Bayesian expression mapping of quantitative trait loci (QTL), i.e. DNA loci that correlate with variations of a phenotypic trait. This analysis identified a locus on chromosome 11q21 associated with Module-1 expression. Among the protein-coding genes contained in this locus, SESN3 was most strongly and positively correlated with Module-1 gene expression in the human and in the mouse epileptic hippocampus. In vitro experiments of silencing and overexpression of SESN3 confirmed its role as regulator of the proconvulsant Module-1 genes. In addition, zebrafish larvae microinjected with SESN3 morpholinos (SESN3 knocked-down), in comparison with control larvae, exhibited a sustained reduction in locomotor activity following exposure to the convulsant agent pentylenetetrazol.
Sestrin 3 belongs to the sestrin family of proteins, 3 proteins that guide the intracellular response to reactive oxygen species (ROS). Sestrins are involved in the deposit of adipose cells, cell metabolism, and mTOR regulation. SESN1 and 2 are a link between oxidative stress, aging, and aging-associated conditions like cancer, diabetes, neurodegenerative diseases, muscular dystrophy, chronic inflammation. Sestrin 3 is the least characterized member of the family [10, 11] .
The following steps, on which we are currently engaged, are to elucidate the role of SESN3 in mammalian epilepsy. To this aim, we generated SESN3 knock-out rats and are currently carrying out a detailed phenotypization, in terms of susceptibility not only to epilepsy and seizures, but also to neuropsychiatric comorbidities, such as anxiety, depression, and cognitive impairment. Such analysis is being performed both in pups and in adults, using an extended battery of tests and epilepsy models (Lovisari et al., in preparation).
These studies illustrate the power of systems genetics applied to epilepsy research: starting from surgically-removed brain tissue of patients with epilepsy, we identified a module of coexpressed genes regulated by a specific factor, SESN3, which may represent a new therapeutic target. The key point is that SESN3 was identified not through its direct effect on a specific parameter (e.g. membrane excitability), but by its relationship to an epileptic gene coexpression network.
Another example of this approach is the study conducted by Delahaye-Duriez and colleagues [12] . Here, a genome-wide coexpression analysis was performed from human brains, autoptic samples from patients that did not experience neurological disorders as compared with a database of mutations known to exist in epileptic encephalopathies.
The modules identified were then tested for enrichment of association with other common forms of epilepsy. In this way, a module of genes was identified (named M30), enriched for de novo mutations and functionally relevant for synaptic transmission, GABA signaling and conduction of nerve impulses. One other interesting result was that, when performing a GWAS analysis using data from the International League against Epilepsy (ILAE), the M30 module resulted significantly enriched of association with focal and generalized epilepsy [12] . Microarrays and RNA-Seq studies showed that M30 genes are downregulated in murine and human epileptic hippocampi. Finally, valproic acid proved capable of restoring expression levels of M30 genes, emphasizing the possibility to employ these systems genetics approaches to develop new pharmacological treatments.
Genome-wide analysis has also been applied to other types of variants, not only SNPs, such as RNA editing events. RNA editing is any posttranscriptional variation that alters nucleotide composition, thereby modifying protein function. Srivastava and colleagues [13] were the first to perform a GWAS study on differential RNA editing (DRE) using an acquired epilepsy model: RNA-Seq of samples from 100 epileptic mice, and 100 healthy controls were analyzed and investigated for functional enrichment with GO or phenotype terms relevant for epilepsy. Genome-wide associations studies analysis identified a set of 256 DRE sites between epileptic and control mice, 134 of which were clustered together. Moreover, GO analysis suggested that the editing affected genes enriched for functional terms related to neural processes, leading to hypothesize a DRE role in epileptogenesis [13] .
Gene networks and miRNAs
Other interesting object of study of the mechanisms leading to the transformation of a healthy into an epileptic brain is the microRNAs (miRNAs). MicroRNAs are small noncoding RNAs (22-25 nucleotides), acting at posttranscriptional level by binding complementary sites on target mRNAs and thereby inhibiting transcription or leading to target RNA degradation, and ultimately controlling protein levels [7] . One single miRNA can target multiple mRNAs, and one mRNA can be regulated by many miRNAs. These characteristics might be exploited to modulate several targets at once, increasing the effect on complex and multidimensional pathologies like epilepsy, but also increasing the risk of offtarget mediated side effects [14] . Indeed, recent studies suggest that these molecules play a key role in the pathogenesis of epilepsy and might be targeted for novel therapeutic approaches [14, 15] .
The question is how to identify the miRNA(s) that represent optimal therapeutic targets for epilepsy. In a microarray study in the pilocarpine model, we identified clusters of miRNAs in the dentate gyrus that separated control and chronic phase rats from those sacrificed during latency or after the first spontaneous seizure [16] . Comparison with data from epileptic patients identified at least 3 miRNAs that were upregulated in both the human and rat epileptic hippocampus. In addition, an overlap could be observed between miRNAs differently expressed during epileptogenesis in our study with those found in other studies that employed a similar approach in different epilepsy models [17, 18] .
In order to select those miRNA that were altered in a disease-and not simply model-dependent manner, we thought to combine data from these 3 studies in a meta-analysis [19] .
This led to the identification of 26 miRNAs differentially expressed during epileptogenesis, 11 of which were not identified in individual studies, and of 5 miRNAs differentially expressed in the chronic period, 11 of which not identified in the individual studies. We also pursued identification of the mRNA targets of these miRNAs. For that, we first performed target prediction using a web-accessible database (miRWalk), but that retrieved a huge number of targets. We than looked for inverse relationship between our miRNAs and mRNAs identified in separate epileptogenesis studies in the same models [20] . We found inverse relationship between 22 (of our 26) miRNAs, and 112 predicated gene targets.
Although these findings potentially disclose mechanisms of epileptogenesis and therapeutic targets that should now be investigated and validated, the number and heterogeneity of identified mRNAs suggest that therapies focused on a single miRNA may not be sufficient to reverse or ameliorate the epileptogenic process. Rather, proper combinations of miRNAs should be targeted together. Nonetheless, existing data suggest that modulation of even a single miRNA may be sufficient to produce significant effects. For example, Jimenez-Mateos and colleagues demonstrated that inhibiting miR-134 after induction of status epilepticus can prevent the occurrence of spontaneous seizures [21] .
Conclusions
The few examples described in this minireview support the notion that studying epilepsy and its comorbidities within a complex systems framework is a promising integration to the traditional reductionist approaches. It should be emphasized that we do not suggest (nor we expect) that the reductionist approaches should be abandoned, because they will certainly continue to advance our knowledge and to contribute new treatments. However, we believe that the concept of network disease is important for improving our understanding of epilepsy, and that the use of techniques that allow a more holistic vision of the changes occurring in complex systems (like systems genetics) will become more and more important for developing new pharmacological therapies, as illustrated by the studies discussed in this article.
